Investigators: Karen Anderson, Ph.D. and Garrick Wallstrom, Ph.D.
Collaborators: Daniel Cramer, M.D., Sc.D. (BWH), Steven Skates, Ph.D.(MGH), Martin McIntosh, Ph.D. (Fred Hutchinson Cancer Research Center), and Rosanne Kho, M.D. (Mayo Clinic) and Garrick Wallstrom, Ph.D.
|Who gets it?
What are the symptoms?
|How do we detect it now?
How is it currently treated?
|What are the current challenges?|
The immune system creates antibodies to both foreign and self proteins, and by developing a way to detect antibodies that target mutant p53 proteins, we may be able to detect ovarian cancer early using patients’ blood. Using NAPPA, we print the most common p53 specific mutant proteins on these slides. If antibodies are made that can bind to mutant p53, our slides may detect them. By comparing healthy to benign patients, we can detect biomarkers that are only in cancerous patients. If detected early enough, these biomarkers may lead to better patient prognosis, or help to distinguish different stages or forms of cancer, which may lead to better personalized treatment.
Figure (from Anderson et al 2010): p53 autoantibodies are highly specific biomarkers in serous ovarian cancer. A, sera derived from 30 ovarian cancer patients and 30 age-matched healthy women were tested for p53-specific antibodies by RAPID ELISA. Dotted line, the cutoff value (columns, mean signal of the controls; bars, SD; 13.1 × 106). B, distribution of p53 autoantibodies in serous cases and controls. The signal intensity for serous cases (n= 60) and all controls (n = 120) are shown as a percentage of the total sera. The distribution of p53-AAb signal intensity for controls (open columns) is a unimodal distribution and the cases show a bimodal distribution (filled columns).
Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, Cramer D. (2010) P53 Autoantibodies As Potential Detection And Prognostic Biomarkers In Serous Ovarian Cancer. Cancer Epidemiology, Biomarkers, and Prevention Mar;19(3):859-68. PMID: 20200435